EU HTA Regulation (EU) 2021/2282 JCA in action

One joint clinical assessment. 27 Member States. One evidence story.

Since January 2025, new health technologies in scope go through an EU-level Joint Clinical Assessment. HEORaccess helps developers turn many national PICO requests into a single, defensible evidence package, from PICO scoping through evidence generation and synthesis to the JCA dossier.

27EU Member States, one assessment
P·I·C·OPopulation, Intervention, Comparator, Outcomes
30days after EC authorisation, the JCA report is due
2030all new centrally authorised medicines in scope

EU JCA network

Procedure #1
EU-27 (JCA) Other European Assessor Co-assessor
 

From PICO to JCA report

Click a step
  1. 1
    PICO scoping
  2. 2
    Consolidation
  3. 3
    Evidence generation
  4. 4
    Evidence synthesis
  5. 5
    Dossier & review
  6. 6
    JCA report

Member States define their PICOs

Each Member State states the population, comparators and outcomes it needs for its own decisions.

PPopulation
IIntervention
CComparator
OOutcomes
Illustrative request from Germany

Many requests, a few consolidated PICOs

The assessor and co-assessor merge national requests into the consolidated PICOs that set the assessment scope.

Evidence generation mapped to every PICO

Evidence gaps against each consolidated PICO are found early, so trials, real-world data and analyses can be planned to close them.

Pivotal RCTReal-world evidenceSubgroupsJoint Scientific Consultation

Evidence synthesis when head-to-head trials are missing

Direct and indirect comparisons against every requested comparator, with transparent handling of uncertainty.

Network meta-analysisMAICSTCSensitivity analyses

JCA dossier and joint review

The developer submits one dossier. The assessors, with patient and clinical experts, review it on a fixed EU timeline.

  • ✓Dossier submitted against all consolidated PICOs
  • ✓Assessor & co-assessor review
  • ✓Patient and clinical expert input
  • ✓Draft report shared for comment
  • ✓Endorsed by the HTA Coordination Group

One EU report, 27 national decisions

The JCA report is published after marketing authorisation. Member States take it into account, but pricing and reimbursement decisions stay national.

Phased scope of the EU JCA

Preparing for an EU JCA? Turn your evidence into access.PICO simulation, systematic reviews and evidence synthesis, NMA and MAIC, real-world evidence, and JCA dossier support.

Discuss a project

PICO examples and procedure animations are illustrative and do not represent a specific product or assessment.

End-to-end EU JCA support

What HEORaccess does at each of the six steps, from the first PICO simulation to national submissions.

  1. PICO scoping

    We simulate the PICOs that Member States are likely to request, so you know the probable scope before it is confirmed.

  2. Consolidation

    We map your evidence against each consolidated PICO and show which questions it answers and which it does not.

  3. Evidence generation

    We plan the reviews, analyses and real-world studies needed to close the gaps while there is still time.

  4. Evidence synthesis

    We run the network meta-analyses, MAICs and STCs for every requested comparator, with sensitivity analyses.

  5. Dossier and review

    We write the JCA dossier against all consolidated PICOs and support responses during the joint review.

  6. JCA report

    We help national teams carry the JCA evidence into each country's pricing and reimbursement submission.

EU JCA questions

What is the EU Joint Clinical Assessment?

The Joint Clinical Assessment (JCA) is a single EU-level assessment of a new health technology's relative clinical effectiveness and safety, set up by the EU HTA Regulation (EU) 2021/2282. One report serves all 27 Member States, which take it into account in their own pricing and reimbursement decisions.

Which products are in scope of the EU JCA, and when?

New oncology medicines and advanced therapy medicinal products have been in scope since January 2025. Selected high-risk medical devices and in vitro diagnostics follow from 2026, orphan medicinal products from January 2028, and all new centrally authorised medicines from January 2030.

What is a PICO in the JCA?

PICO stands for Population, Intervention, Comparator and Outcomes. Each Member State states the PICOs it needs for its own decisions. The assessor and co-assessor consolidate these into the set of PICOs that defines the scope of the assessment.

Does the JCA decide pricing and reimbursement?

No. The JCA covers relative clinical effectiveness and safety only. Economic evaluation, pricing and reimbursement decisions stay with each Member State.